(Q37634598)

21 August 2017

1 reference

title

Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer (English)

1 reference

21 August 2017

1

1 reference

21 August 2017

2

Yasushi Yatabe

1 reference

PubMed ID

19922469

21 August 2017

language of work or name

English

0 references

publication date

18 November 2009

1 reference

21 August 2017

1 reference

21 August 2017

277

1 reference

21 August 2017

301-308

1 reference

21 August 2017

2

1 reference

The discovery of receptor tyrosine kinases: targets for cancer therapy

21 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2009.07448.X

An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2009.07448.X

ERBB receptors and cancer: the complexity of targeted inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2009.07448.X

The epidermal growth factor receptor ligands at a glance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2009.07448.X

An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2009.07448.X

Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2009.07448.X

Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2009.07448.X

Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2009.07448.X

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2009.07448.X

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2009.07448.X

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2009.07448.X

Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2009.07448.X

Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2009.07448.X

Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2009.07448.X

TTF-1 expression in pulmonary adenocarcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2009.07448.X

EGFR mutation is specific for terminal respiratory unit type adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2009.07448.X

Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2009.07448.X

Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2009.07448.X

Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2009.07448.X

Epidermal growth factor receptor mutants from human lung cancers exhibit enhanced catalytic activity and increased sensitivity to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2009.07448.X

The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2009.07448.X

Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2009.07448.X

Epidermal growth factor receptor gene amplification is acquired in association with tumor progression of EGFR-mutated lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2009.07448.X

Somatic mutations of the HER2 kinase domain in lung adenocarcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2009.07448.X

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2009.07448.X

EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2009.07448.X

Risk factors differ for non-small-cell lung cancers with and without EGFR mutation: assessment of smoking and sex by a case-control study in Japanese

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2009.07448.X

10.1111/J.1742-4658.2009.07448.X

21 January 2018

Identifiers

DOI

1 reference

21 August 2017

1 reference

PubMed ID

19922469